𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers

✍ Scribed by Kunitoshi Tomii; Kazunori Tsukuda; Shinichi Toyooka; Hideaki Dote; Tadashi Hanafusa; Hiroaki Asano; Minoru Naitou; Hiroyoshi Doihara; Takumi Kisimoto; Hideki Katayama; Harvery I. Pass; Hiroshi Date; Nobuyoshi Shimizu

Publisher
John Wiley and Sons
Year
2006
Tongue
French
Weight
514 KB
Volume
120
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Insulin‐like growth factor binding protein‐3 (IGFBP‐3) is postulated to be a mediator of growth suppression signals. Here, we examined the methylation status of IGFBP‐3 to correlate to clinicopathological factors in human cancers. The methylation status of IGFBP‐3 was determined by bisulfite DNA sequencing and was correlated with expression semi‐quantified by real‐time RT‐PCR to develop a methylation‐specific PCR (MSP) assay for IGFBP‐3. Using the MSP assay, we examined the methylation status of IGFBP‐3 in gastric cancer (GC), colorectal cancer (CRC), breast cancer (BC) and malignant mesothelioma (MM). IGFBP‐3 methylation was detected in 6 of 13 (46%) and 16 of 24 (67%) GC cell lines and tumors, respectively; 4 of 8 (50%) and 15 of 26 (58%) CRC cell lines and tumors, respectively; 3 of 11 (27%) and 7 of 39 (18%) BC cell lines and tumors, respectively and 1 of 5 (20%) and 18 of 56 (32%) MM cell lines and tumors, respectively. Interestingly, the methylation status of MM specimens from Japanese patients (75%, 12 out of 16 patients) was significantly higher than those from the USA (15%, 6 out of 40 patients) (p < 0.0001), suggesting the presence of ethnic differences in the IGFBP‐3 methylation status. We also found that IGFBP‐3 methylation was preferentially present in GCs arising in the lower‐third of the stomach (p = 0.079). In summary, our results showed that IGFBP‐3 methylation played an important role in the silencing of its expression, suggesting that IGFBP‐3 may act as a tumor suppressor gene in several human cancers examined. © 2006 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Aberrant promoter methylation of human D
Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers
✍ Masaaki Yano; Shinichi Toyooka; Kazunori Tsukuda; Hideaki Dote; Mamoru Ouchida; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 767 KB

## Abstract The human DOC‐2/DAB2 interactive protein gene (__hDAB2IP__) is a novel member of the Ras GTPase‐activating gene family that is known to act as a tumor suppressor gene and is inactivated by methylation in prostate and breast cancers. We established previously a methylation‐specific PCR (

Role of insulin-like growth factor bindi
Role of insulin-like growth factor binding protein-3 in breast cancer cell growth
✍ Lynette J. Schedlich; Lloyd D. Graham 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB 👁 1 views

The mitogenic effects of insulin-like growth factors (IGFs) are regulated by a family of insulin-like growth factor binding proteins (IGFBPs). One member of this family, IGFBP-3, mediates the growth-inhibitory and apoptosis-inducing effects of a number of growth factors and hormones such as transfor

Serum insulin-like growth factor-I, insu
Serum insulin-like growth factor-I, insulin-like growth factor binding protein-3, and the risk of pancreatic cancer death
✍ Yingsong Lin; Akiko Tamakoshi; Shogo Kikuchi; Kiyoko Yagyu; Yuki Obata; Teruo Is 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 75 KB 👁 1 views

## Abstract Recent epidemiological studies have shown that high serum levels of insulin‐like growth factor‐I (IGF‐I) are associated with an increased risk of lung, colon, breast and prostate cancer. Since very few studies have addressed the role of serum levels of IGF‐I in the development of pancre

Insulin-like growth factor binding prote
Insulin-like growth factor binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells
✍ C.A. Fowler; C.M. Perks; P.V. Newcomb; P.B. Savage; J.R. Farndon; J.M.P. Holly 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 145 KB 👁 2 views

Variability in response to chemotherapy is poorly understood. Paclitaxel-induced apoptosis was assessed in human Hs578T breast cancer cells, using the MTT assay, cell counting, morphological features and flow cytometry. Pre-dosing cells with non-glycosylated insulin-like growth factor binding protei

Promoter −202 A/C polymorphism of insuli
Promoter −202 A/C polymorphism of insulin-like growth factor binding protein-3 gene and non-small cell lung cancer risk
✍ Jin Wook Moon; Yoon Soo Chang; Chul Woo Ahn; Kyeong Nam Yoo; Ju Hye Shin; Jee Hy 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 93 KB

Insulin-like growth factor binding protein-3 (IGFBP-3) inhibits the mitogenic and antiapoptotic activity of insulin-like growth factor (IGF) by blocking the binding of IGF to its receptor. However, under certain circumstances, IGFBP-3 can enhance the activity of IGF by protecting IGF from degradatio